HC Wainwright Analysts Give Omeros (OMER) a $30.00 Price Target

HC Wainwright set a $30.00 price target on Omeros (NASDAQ:OMER) in a research note released on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also issued reports on OMER. Maxim Group set a $24.00 price target on shares of Omeros and gave the stock a buy rating in a research note on Thursday, February 15th. ValuEngine lowered shares of Omeros from a hold rating to a sell rating in a research note on Wednesday, February 14th. Zacks Investment Research lowered shares of Omeros from a buy rating to a hold rating in a research note on Wednesday, October 25th. Bank of America upped their target price on shares of Omeros from $2.44 to $4.00 in a research note on Wednesday, February 14th. Finally, Wedbush restated an outperform rating and set a $47.00 target price on shares of Omeros in a research note on Tuesday, November 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $30.38.

Shares of Omeros (NASDAQ OMER) opened at $9.00 on Monday. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. The stock has a market cap of $432.03, a PE ratio of -6.98 and a beta of 3.30. Omeros has a one year low of $8.66 and a one year high of $27.09.

Several hedge funds have recently added to or reduced their stakes in OMER. Alliancebernstein L.P. increased its stake in shares of Omeros by 40.1% during the second quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company’s stock worth $1,224,000 after buying an additional 17,600 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Omeros by 39.4% during the second quarter. TIAA CREF Investment Management LLC now owns 149,252 shares of the biopharmaceutical company’s stock worth $2,971,000 after buying an additional 42,165 shares during the period. Ameriprise Financial Inc. purchased a new stake in shares of Omeros during the second quarter worth approximately $971,000. Northern Trust Corp increased its stake in shares of Omeros by 6.4% during the second quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock worth $11,397,000 after buying an additional 34,328 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Omeros by 5.4% during the second quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after buying an additional 94,280 shares during the period. Hedge funds and other institutional investors own 50.95% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “HC Wainwright Analysts Give Omeros (OMER) a $30.00 Price Target” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/hc-wainwright-analysts-give-omeros-omer-a-30-00-price-target/1907540.html.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.